241 related articles for article (PubMed ID: 38338729)
41. Involvement of Src tyrosine kinases (SFKs) and of focal adhesion kinase (FAK) in the injurious mechanism in rat primary neuronal cultures exposed to chemical ischemia.
Shani V; Bromberg Y; Sperling O; Zoref-Shani E
J Mol Neurosci; 2009 Jan; 37(1):50-9. PubMed ID: 18584337
[TBL] [Abstract][Full Text] [Related]
42. Fyn is an important molecule in cancer pathogenesis and drug resistance.
Elias D; Ditzel HJ
Pharmacol Res; 2015 Oct; 100():250-4. PubMed ID: 26305432
[TBL] [Abstract][Full Text] [Related]
43. Src family kinases and paclitaxel sensitivity.
Le XF; Bast RC
Cancer Biol Ther; 2011 Aug; 12(4):260-9. PubMed ID: 21646863
[TBL] [Abstract][Full Text] [Related]
44. Elevated c-Src and c-Yes expression in malignant skin cancers.
Lee JH; Pyon JK; Kim DW; Lee SH; Nam HS; Kim CH; Kang SG; Lee YJ; Park MY; Jeong DJ; Cho MK
J Exp Clin Cancer Res; 2010 Aug; 29(1):116. PubMed ID: 20796316
[TBL] [Abstract][Full Text] [Related]
45. S-nitrosylation at cysteine 498 of c-Src tyrosine kinase regulates nitric oxide-mediated cell invasion.
Rahman MA; Senga T; Ito S; Hyodo T; Hasegawa H; Hamaguchi M
J Biol Chem; 2010 Feb; 285(6):3806-3814. PubMed ID: 19948721
[TBL] [Abstract][Full Text] [Related]
46. Overexpression of YES1 is associated with favorable prognosis and increased platinum-sensitivity in patients with epithelial ovarian cancer.
Zhou Y; Chen P; Huang Q; Wan T; Jiang Y; Jiang S; Yan S; Zheng M
Histol Histopathol; 2020 Jul; 35(7):721-728. PubMed ID: 31970720
[TBL] [Abstract][Full Text] [Related]
47. Up-regulation of microRNA-210 inhibits proliferation of hepatocellular carcinoma cells by targeting YES1.
Tan W; Lim SG; Tan TM
World J Gastroenterol; 2015 Dec; 21(46):13030-41. PubMed ID: 26676187
[TBL] [Abstract][Full Text] [Related]
48. Downregulation of circ-YES1 suppresses NSCLC migration and proliferation through the miR-142-3p-HMGB1 axis.
Jin M; Wang Y; Zhou D; Liu W; Han R; Chi Y
Respir Res; 2023 Apr; 24(1):100. PubMed ID: 37009887
[TBL] [Abstract][Full Text] [Related]
49. Endogenous and synthetic inhibitors of the Src-family protein tyrosine kinases.
Chong YP; Ia KK; Mulhern TD; Cheng HC
Biochim Biophys Acta; 2005 Dec; 1754(1-2):210-20. PubMed ID: 16198159
[TBL] [Abstract][Full Text] [Related]
50. Resequencing analysis of the human tyrosine kinase gene family in pancreatic cancer.
Kubo T; Kuroda Y; Kokubu A; Hosoda F; Arai Y; Hiraoka N; Hirohashi S; Shibata T
Pancreas; 2009 Oct; 38(7):e200-6. PubMed ID: 19893451
[TBL] [Abstract][Full Text] [Related]
51. Understanding the cellular roles of Fyn-related kinase (FRK): implications in cancer biology.
Goel RK; Lukong KE
Cancer Metastasis Rev; 2016 Jun; 35(2):179-99. PubMed ID: 27067725
[TBL] [Abstract][Full Text] [Related]
52. [SRC kinases in tumor therapy].
Dempke W; Zippel R
Med Klin (Munich); 2010 Oct; 105(10):711-5. PubMed ID: 20981590
[TBL] [Abstract][Full Text] [Related]
53. YES1 Is a Druggable Oncogenic Target in SCLC.
Redin E; Garrido-Martin EM; Valencia K; Redrado M; Solorzano JL; Carias R; Echepare M; Exposito F; Serrano D; Ferrer I; Nunez-Buiza A; Garmendia I; García-Pedrero JM; Gurpide A; Paz-Ares L; Politi K; Montuenga LM; Calvo A
J Thorac Oncol; 2022 Dec; 17(12):1387-1403. PubMed ID: 35988891
[TBL] [Abstract][Full Text] [Related]
54. Role of co- and post-translational modifications of SFKs in their kinase activation.
Cai ML; Wang MY; Zhang CH; Wang JX; Liu H; He HW; Zhao WL; Xia GM; Shao RG
J Drug Target; 2020 Jan; 28(1):23-32. PubMed ID: 31094236
[TBL] [Abstract][Full Text] [Related]
55. SRC kinase-mediated signaling pathways and targeted therapies in breast cancer.
Luo J; Zou H; Guo Y; Tong T; Ye L; Zhu C; Deng L; Wang B; Pan Y; Li P
Breast Cancer Res; 2022 Dec; 24(1):99. PubMed ID: 36581908
[TBL] [Abstract][Full Text] [Related]
56. Activation of Src family kinases in Neu-induced mammary tumors correlates with their association with distinct sets of tyrosine phosphorylated proteins in vivo.
Muthuswamy SK; Muller WJ
Oncogene; 1995 Nov; 11(9):1801-10. PubMed ID: 7478608
[TBL] [Abstract][Full Text] [Related]
57. Predictive Biomarkers of Response to Src Inhibitors in Lung Cancer. Getting to YES1.
Li HY; Carr LL
Am J Respir Crit Care Med; 2019 Oct; 200(7):802-804. PubMed ID: 31206303
[No Abstract] [Full Text] [Related]
58. MiR-133 Targets YES1 and Inhibits the Growth of Triple-Negative Breast Cancer Cells.
Zhang G; Wang J; Zheng R; Song B; Huang L; Liu Y; Hao Y; Bai X
Technol Cancer Res Treat; 2020; 19():1533033820927011. PubMed ID: 32462982
[TBL] [Abstract][Full Text] [Related]
59. IGF-1R Inhibition Activates a YES/SFK Bypass Resistance Pathway: Rational Basis for Co-Targeting IGF-1R and Yes/SFK Kinase in Rhabdomyosarcoma.
Wan X; Yeung C; Heske C; Mendoza A; Helman LJ
Neoplasia; 2015 Apr; 17(4):358-66. PubMed ID: 25925378
[TBL] [Abstract][Full Text] [Related]
60. Activated SRC protein tyrosine kinase is overexpressed in late-stage human ovarian cancers.
Wiener JR; Windham TC; Estrella VC; Parikh NU; Thall PF; Deavers MT; Bast RC; Mills GB; Gallick GE
Gynecol Oncol; 2003 Jan; 88(1):73-9. PubMed ID: 12504632
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
